Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
AC Immune S.A. (ACIU)
AC Immune S.A. (ACIU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
AC Immune: Q3 Earnings Snapshot

AC Immune: Q3 Earnings Snapshot

ACIU : 3.85 (+6.35%)
AC Immune: Q2 Earnings Snapshot

AC Immune: Q2 Earnings Snapshot

ACIU : 3.85 (+6.35%)
Why Shares of AC Immune Jumped This Week

The FDA has granted a Fast Track Designation to its Alzheimer's disease vaccine candidate.

ACIU : 3.85 (+6.35%)
AC Immune: Q1 Earnings Snapshot

AC Immune: Q1 Earnings Snapshot

ACIU : 3.85 (+6.35%)
Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance

Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.

BIIB : 220.95 (+1.82%)
LLY : 782.12 (+3.77%)
ACET : 2.40 (+2.13%)
ACIU : 3.85 (+6.35%)
Is Ardelyx is A Buy After Slip in Early 2022

Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them

ARDX : 9.34 (+0.21%)
CNCE : 8.37 (+0.12%)
KYKOF : 20.2872 (+3.14%)
SFOSF : 1.8525 (+4.66%)
KHTRF : 4.0900 (+0.99%)
ACIU : 3.85 (+6.35%)
BMEA : 17.81 (+1.77%)
AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of 29.17% and 457.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ACIU : 3.85 (+6.35%)
THMO : 0.8349 (-3.92%)
AC Immune: Q3 Earnings Snapshot

AC Immune: Q3 Earnings Snapshot

ACIU : 3.85 (+6.35%)
Detailed Data From the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC

Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year studyAs previously reported, numerical differences...

ACIU : 3.85 (+6.35%)
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ACIU : 3.85 (+6.35%)
VRTX : 432.76 (+2.86%)

Barchart Exclusives

PMI, Powell and Other Key Things to Watch This Week
This week we still have earnings, PMI and we also have Powell testifying, some inflation data, and Non-Farm payrolls out Friday. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar